Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease

Background: Chronic kidney disease (CKD) is a very common long-term condition and powerful risk factor for cardiovascular disease (CVD). Low-dose aspirin is of proven benefit in the secondary prevention of myocardial infarction (MI) and stroke in people with pre-existing CVD. However, in people with...

Full description

Bibliographic Details
Main Authors:	Dumbleton, J. (Author), Fitzmaurice, D. (Author), Fraser, S.D (Author), Fuat, A. (Author), Gallagher, H. (Author), Griffith, K.E (Author), Hawkey, C.J (Author), Henderson, R.A (Author), Lord, J. (Author), Lown, M. (Author), Maishman, T. (Author), Moore, M.V (Author), Roderick, P.J (Author), Stevens, P. (Author), Stevenson, D. (Author), Taal, M.W (Author), Whitehead, A. (Author)
Format:	Article
Language:	English
Published:	BioMed Central Ltd 2022
Subjects:	Aspirin Cardiovascular disease Chronic kidney disease Primary care Primary prevention
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Internet

Similar Items